Current:Home > MyObesity drug Wegovy cut risk of serious heart problems by 20%, study finds-Angel Dreamer Wealth Society D1 Reviews & Insights
Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds
View Date:2024-12-23 21:01:40
The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.
The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease — but not diabetes.
The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them.
“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.
Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don’t have that disease.
Experts have known for years that losing weight can improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.
“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.
In the U.S., there are about 6.6 million people like those tested in the study, experts said.
The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. Novo Nordisk, the maker of Wegovy and Ozempic, has asked the U.S. Food and Drug Administration to include the heart benefits on Wegovy’s label, like on Ozempic’s.
The new study, paid for by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher and were tracked for more than three years on average. They took typical drugs for their heart conditions, but they were also randomly assigned to receive weekly injections of Wegovy or a dummy shot.
The study found that 569, or 6.5%, of those who got the drug versus 701, or 8%, of those who received the dummy shot had a heart attack or stroke or died from a heart-related cause. That’s an overall reduction of 20% in the risk of those outcomes, the researchers reported.
The drop appeared to be fueled primarily by the difference in heart attacks, but the number of serious health complications reported were too small to tell whether the individual outcomes were caused by the drug or by chance.
Study volunteers who took Wegovy lost about 9% of their weight while the placebo group lost less than 1%.
The Wegovy group also saw drops in key markers of heart disease, including inflammation, cholesterol, blood sugars, blood pressure and waist circumference, noted Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles. Changes in those markers began early in the study, before participants lost much weight.
“It means to me that it’s more than just weight loss, how this drug works,” said Gulati, who had no role in what she called a landmark study.
Still, “it remains unclear” how much of the results were a benefit of losing weight or the drug itself, an editorial accompanying the study noted.
About a third of all study volunteers reported serious side effects. About 17% in the Wegovy group and about 8% in the comparison group left the study, mostly because of nausea, vomiting, diarrhea and other stomach-related problems.
Nearly three-quarters of participants were men and nearly 84% were white. Gulati and others said future research needs to include more women and racial and ethnic minorities.
Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, a version of the diabetes drug Mounjaro, for weight control.
Both carry high price tags — monthly costs are about $1,300 for Wegovy and about $1,000 for Zepbound. And both have been in shortage for months, with manufacturers promising to boost supplies.
The medications are often not covered by private health insurance or subject to strict preauthorization requirements. Medicare, the government health plan for older Americans, is prohibited from covering drugs for weight loss alone. But drugmakers and obesity treatment advocates have been pushing for broader coverage, including asking Congress to pass legislation to mandate that Medicare pay for the drugs.
Results from the latest study and others that show the obesity drugs have a direct effect on costly health problems could be a factor in shifting the calculus of coverage, said Dr. Mark McClellan, former chief of the Centers for Medicare and Medicaid Services and the FDA. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.
That approach “may end up being relevant here,” he said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
veryGood! (2)
Related
- Eminem, Alanis Morissette, Sheryl Crow, N.W.A. and Janet Jackson get Songwriters Hall of Fame nods
- Deion Sanders searching for Colorado's identity after loss to USC: 'I don't know who we are'
- Sen. Dianne Feinstein, pioneering LGBTQ ally, celebrated and mourned in San Francisco
- Last Netflix DVDs being mailed out Friday, marking the end of an era
- Teachers in 3 Massachusetts communities continue strike over pay, paid parental leave
- $11 million settlement reached in federal suits over police shooting of girl outside football game
- It's only fitting Ukraine gets something that would have belonged to Russia
- 1 mountain climber's unique mission: to scale every county peak in Florida
- Homes of Chiefs’ quarterback Mahomes and tight end Kelce were broken into last month
- Simone Biles soars despite having weight of history on her at worlds
Ranking
- Queen Bey and Yale: The Ivy League university is set to offer a course on Beyoncé and her legacy
- Man convicted of killing ex-girlfriend, well-known sex therapist in 2020
- Rep. Jamaal Bowman pulls fire alarm ahead of House vote to fund government
- Where poor air quality is expected in the US this week
- It's cozy gaming season! Video game updates you may have missed, including Stardew Valley
- Roof of a church collapses during a Mass in northern Mexico, trapping about 30 people in the rubble
- A populist ex-premier who opposes support for Ukraine leads his leftist party to victory in Slovakia
- AP Top 25 Takeaways: Should Georgia still be No. 1? Leaving Prime behind. Hard to take USC seriously
Recommendation
-
Just Eat Takeaway sells Grubhub for $650 million, just 3 years after buying the app for $7.3 billion
-
The Supreme Court’s new term starts Monday. Here’s what you need to know
-
South Korean golfers Sungjae Im & Si Woo Kim team for win, exemption from military service
-
Afghan Embassy closes in India citing a lack of diplomatic support and personnel
-
Harriet Tubman posthumously honored as general in Veterans Day ceremony: 'Long overdue'
-
Africa at a crossroads as more democracies fall to military coups, experts say
-
Why former Northwestern coach Pat Fitzgerald was at the Iowa-Michigan State game
-
NASCAR Talladega playoff race 2023: Start time, TV, streaming, lineup for YellaWood 500